Emetine regulates the alternative splicing of caspase 9 in tumor cells
- Authors:
- Danmin Pan
- Kritsanapol Boon-Unge
- Piyarat Govitrapong
- Jianhua Zhou
View Affiliations
Affiliations: JiangSu Key Laboratory of Neuroregeneration, Nantong University, Nantong, Jiangsu 226001, P.R. China, Neuro-Behavioural Biology Center, Mahidol University, Salaya, Nakornpathom 73170, Thailand
- Published online on: August 29, 2011 https://doi.org/10.3892/ol.2011.395
-
Pages:
1309-1312
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Exons 3 to 6 in the caspase 9 gene undergo alternative splicing in which the larger caspase 9 splice variant promotes apoptosis, in contrast to the dominant negative anti-apoptotic splice variant, the smaller caspase 9b. In this study, the regulation of the alternative splicing of caspase 9 pre-mRNA was examined in response to Emetine. Treatment of C33A cells, breast cancer MCF-7 cells and MCF-7/Adr cells with Emetine dihydrochloride upregulated the level of smaller caspase 9b mRNA and concomitantly decreased the mRNA level of larger caspase 9 in a dose- and time-dependent manner, indicating that Emetine desensitizes C33A, MCF-7 and MCF-7/Adr to cell death. In contrast, treatment of PC3 cells, a prostate cancer cell line, manifested an opposite effect: a greater production of the larger caspase 9 mRNA with a concomitant decrease of caspase 9b mRNA. Pretreatment with calyculin A, an inhibitor of protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) blocked Emetine-induced alternative splicing in cells, in contrast to okadaic acid, a specific inhibitor of PP2A, demonstrating a PP1-mediated mechanism. These results suggest that the various splicing patterns of the caspase 9 gene that are regulated by chemotherapy reagents may contribute to the resistance or sensitization of the tumors to other cell death inducers.
View References
|
1
|
Mercatante D and Kole R: Modification of
alternative splicing pathways as a potential approach to
chemotherapy. Pharmacol Ther. 85:237–243. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Black DL: Protein diversity from
alternative splicing: a challenge for bioinformatics and
post-genome biology. Cell. 103:367–370. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Graveley BR: Alternative splicing:
increasing diversity in the proteomic world. Trends Genet.
17:100–107. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Goldstrohm AC, Greenleaf AL and
Garcia-Blanco MA: Co-transcriptional splicing of pre-messenger
RNAs: considerations for the mechanism of alternative splicing.
Gene. 277:31–47. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Caceres JF and Kornblihtt AR: Alternative
splicing: multiple control mechanisms and involvement in human
disease. Trends Genet. 18:186–193. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Modrek B and Lee C: A genomic view of
alternative splicing. Nat Genet. 30:13–19. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Krawczak M, Reiss J and Cooper DN: The
mutational spectrum of single base-pair substitutions in mRNA
splice junctions of human genes: causes and consequences. Hum
Genet. 90:41–54. 1992. View Article : Google Scholar
|
|
8
|
Schwerk C and Schulze-Osthoff K:
Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell.
19:1–13. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Johnson CR and Jarvis WD: Caspase-9
regulation: an update. Apoptosis. 9:423–427. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moore MJ, Wang Q, Kennedy CJ and Silver
PA: An alternative splicing network links cell-cycle control to
apoptosis. Cell. 142:625–636
|
|
11
|
Chalfant CE, Rathman K, Pinkerman RL, et
al: De novo ceramide regulates the alternative splicing of caspase
9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on
protein phosphatase-1. J Biol Chem. 277:12587–12595. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Massiello A and Chalfant CE: SRp30a
(ASF/SF2) regulates the alternative splicing of caspase-9 pre-mRNA
and is required for ceramide-responsiveness. J Lipid Res.
47:892–897. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Merdzhanova G, Edmond V, De Seranno S, et
al: E2F1 controls alternative splicing pattern of genes involved in
apoptosis through upregulation of the splicing factor SC35. Cell
Death Differ. 15:1815–1823. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grollman AP: Inhibitors of protein
biosynthesis. V Effects of emetine on protein and nucleic acid
biosynthesis in HeLa cells. J Biol Chem. 243:4089–4094.
1968.PubMed/NCBI
|
|
15
|
Boon-Unge K, Yu Q, Zou T, Zhou A,
Govitrapong P and Zhou J: Emetine regulates the alternative
splicing of Bcl-x through a protein phosphatase 1-dependent
mechanism. Chem Biol. 14:1386–1392. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jondorf WR, Abbott BJ, Greenberg NH and
Mead JA: Increased lifespan of leukemic mice treated with drugs
related to (-)-emetine. Chemotherapy. 16:109–129. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Johnson RK and Jondorf WR: Some inhibitory
effects of (--)-emetine on growth of Ehrlich ascites carcinoma.
Biochem J. 140:87–94. 1974.PubMed/NCBI
|
|
18
|
Panettiere F and Coltman CA Jr: Experience
with emetine hydrochloride (NSC 33669) as an antitumor agent.
Cancer. 27:835–841. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Siddiqui S, Firat D and Olshin S: Phase II
study of emetine (NSC-33669) in the treatment of solid tumors.
Cancer Chemother Rep. 57:423–428. 1973.PubMed/NCBI
|
